A synergistic drug combination that aids our battle against anaplastic thyroid carcinoma: a case report and discussion
Open Access
- 25 November 2025
- journal article
- review article
- Published by Springer Nature in Hormones
- Vol. 25 (1) , 267-271
Abstract
Background: Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy historically associated with a poor prognosis and a median survival of only 3.16 months. However, recent advances in molecular profiling and immunotherapy are improving outcomes. Case presentation: We report the case of a 68-year-old man diagnosed with stage IVC ATC who achieved sustained disease stabilisation and long-term survival. Initial treatment with chemotherapy and radiotherapy led to partial remission of the primary tumour, although there was progression of metastatic disease. The patient was subsequently enrolled in a clinical trial investigating an anti-PD-L1 antibody with positive test results, followed by treatment with pembrolizumab. The latter resulted in nearly 11 years of disease control without significant adverse effects, an exceptional outcome in the context of ATC. Conclusion: This case underscores the transformative potential of immunotherapy in the management of advanced ATC and highlights the importance of continued research into combinatorial therapeutic strategies and predictive biomarkers to optimise treatment outcomes.Keywords
Funding Information
- Universidad de Navarra
This publication has 19 references indexed in Scilit:
- Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based studyJournal of Cancer Research and Clinical Oncology, 2022
- Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid CarcinomaThyroid®, 2021
- 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid CancerThyroid®, 2021
- Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 CasesThyroid®, 2020
- Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019JAMA Oncology, 2020
- Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
BRAF
V600E
-Mutated Anaplastic Thyroid CarcinomaThyroid®, 2019
- Diagnosis and Management of Anaplastic Thyroid CancerEndocrinology and Metabolism Clinics of North America, 2019
- Características de profesionalidad de los especialistas y ventajas de los equipos multidisciplinares en cáncer de tiroides: resultados de una encuesta de opinión nacionalEndocrinología, Diabetes y Nutrición, 2019
- The role of surgery in anaplastic thyroid cancer: A systematic reviewAmerican Journal of Otolaryngology, 2017
- Spanish consensus for the management of patients with anaplastic cell thyroid carcinomaEndocrinología y Nutrición, 2015